Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta to Sell $6M in Stock in Private Offerings

Premium

Rosetta Genomics said this week that it has signed definitive agreements to sell an aggregate of $6 million in securities in concurrent private placement and registered direct offerings.

In the private placement, Rosetta will sell roughly 4.5 million ordinary shares at $0.60 each. Purchasers of the stock will also receive warrants to buy up to about 3.4 million more shares at $0.80 apiece.

In the direct offering, the company will sell approximately 5.5 million shares at $0.60 a share. Purchasers will also receive warrants to buy up to 2.7 million more shares at $0.80 per share.

Closing of the offerings is expected to occur around the end of February.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.